Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Iwata, Nobuhisa ^a,b   Sekiguchi, Misaki ^a   Hattori, Yoshino ^b   Takahashi, Akane ^b   Asai, Masashi ^b   Ji, Bin ^c   Higuchi, Makoto ^c   Staufenbiel, Matthias ^d   Muramatsu, Shin Ichi ^e   Saido, Takaomi C ^a  

^a RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^d NOVARTIS PHARMA AG   (Switzerland)

^e JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE METALLOENDOPEPTIDASE;

ADENO ASSOCIATED VIRUS; ALZHEIMER DISEASE; ANIMAL; ARTICLE; GENE EXPRESSION PROFILING; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HIPPOCAMPUS; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MOUSE;

ALZHEIMER DISEASE; ANIMALS; DEPENDOVIRUS; GENE EXPRESSION PROFILING; GENETIC VECTORS; HIPPOCAMPUS; INJECTIONS, INTRAVENOUS; MICE; NEPRILYSIN; TRANSDUCTION, GENETIC;

EID: 84875866006     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep01472     Document Type: Article

References (36)

1. Hardy, J. & Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356 (2002). (Pubitemid 34790756)
2. Iwata, N., Higuchi, M. & Saido, T. C. Metabolism of amyloid-b peptide and Alzheimer's disease. Pharmacol. Ther. 108, 129-148 (2005). (Pubitemid 41527082)
3. Iwata, N. et al. Identification of the major Ab1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat. Med. 6, 143-150 (2000). (Pubitemid 30082357)
4. Iwata, N. et al. Metabolic regulation of brain Ab by neprilysin. Science 292, 1550-1552 (2001).
5. Huang, S. M. et al. Neprilysin-sensitive synapse-associated amyloid-b peptide oligomers impair neuronal plasticity and cognitive function. J. Biol. Chem. 281, 17941-17951 (2006).
6. Iwata, N. et al. Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-b peptide in mouse brain. J. Neurosci. 24, 991-998 (2004). (Pubitemid 38146610)
7. Nilsson, P. et al. Gene therapy in Alzheimer's disease-potential for disease modification. J. Cell. Mol. Med. 14, 741-757 (2010).
8. Muramatsu, S. et al. A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. Mol. Ther. 18, 1731-1735 (2010).
9. Christine, C. W. et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 73, 1662-1669 (2009).
10. Lu, B. et al. Neutral endopeptidase modulation of septic shock. J. Exp. Med. 181, 2271-2275 (1995).
11. Sturchler-Pierrat, C. et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. USA 94, 13287-13292 (1997). (Pubitemid 27518514)
12. Miyakawa, T. et al.Neurogranin null mutant mice display performance deficits on spatial learning tasks with anxiety related components. Hippocampus 11, 763-775 (2001). (Pubitemid 34065506)
13. Maeda, J. et al. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J. Neurosci. 27, 10957-10968 (2007). (Pubitemid 47574168)
14. Maeda, J. et al. In vivo positron emission tomographic imaging of glial responses to amyloid-b and tau pathologies in mouse models of Alzheimer's disease and related disorders. J. Neurosci. 31, 4720-4730 (2011).
15. Ji, B. et al. Imaging of peripheral benzodiazepine receptor expression as biomarkers of detrimental versus beneficial glial responses in mouse models of Alzheimer's and other CNS pathologies. J. Neurosci. 28, 12255-12267 (2008).
16. Saido, T. C. et al. Dominant and differential deposition of distinct b-amyloid peptide species, AbN3(pE), in senile plaques. Neuron 14, 457-466 (1995).
17. Haass, C. & Selkoe, D. J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid b-peptide. Nat. Rev. Mol. Cell. Biol. 8, 101-112 (2007). (Pubitemid 46432529)
18. Benilova, I., Karran, E. & De Strooper, B. The toxic Ab oligomer and Alzheimer's disease: an emperor in need of clothes. Nat. Neurosci. 15, 349-357 (2012).
19. Larson, M. E. & Lesné, S. E. Soluble Ab oligomer production and toxicity. J. Neurochem. 120 Suppl 1, 125-139 (2012).
20. Foust, K. D. et al. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 27, 59-65 (2009).
21. Petrs-Silva, H. et al. Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol. Ther. 19, 293-301 (2011).
22. Cirrito, J. R. et al. Endocytosis is required for synaptic activity-dependent release of amyloid-b in vivo. Neuron 58, 42-51 (2008). (Pubitemid 351467029)
23. Walsh, D. M. et al. Naturally secreted oligomers of amyloid b protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539 (2002). (Pubitemid 34288854)
24. Abramov, E. et al. Amyloid-b as a positive endogenous regulator of release probability at hippocampal synapses. Nat. Neurosci. 12, 1567-1576 (2009).
25. Bharadwaj, P. R. et al. Ab aggregation and possible implications in Alzheimer's disease pathogenesis. J. Cell. Mol. Med. 13, 412-421 (2009).
26. Kerr, M. A. & Kenny, A. J. The molecular weight and properties of a neutral metallo-endopeptidase from rabbit kidney brush border. Biochem. J. 137, 489-495 (1974).
27. Selkoe, D. J. Alzheimer's disease is a synaptic failure. Science 298, 789-791 (2002). (Pubitemid 35231524)
28. Holmes, C. et al. Long-term effects of Ab42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372, 216-223 (2008). (Pubitemid 351978111)
29. Schilling, S. et al. On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). Biochemistry 45, 12393-12399 (2006). (Pubitemid 44583682)
30. Nussbaum, J. M. et al. Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-b. Nature 485, 651-655 (2012).
31. Schilling, S. et al. Glutaminyl cyclase inhibition attenuates pyroglutamate Ab and Alzheimer's disease-like pathology. Nat. Med. 14, 1106-1111 (2008).
32. Gao, G. et al. Clades of adeno-associated viruses are widely disseminated in human tissues. J. Virol. 78, 6381-6388 (2004). (Pubitemid 38715936)
33. Li, X. G. et al. Viral-mediated temporally controlled dopamine production in a rat model of Parkinson disease. Mol. Ther. 13, 160-166 (2006).
34. Fukami, S. et al. Ab-degrading endopeptidase, neprilysin, in mouse brain: synaptic and axonal localization inversely correlating with Ab pathology. Neurosci. Res. 43, 39-56 (2002). (Pubitemid 34628582)
35. Tai, Y. C. et al. Performance evaluation of the microPET focus: a third generation microPET scanner dedicated to animal imaging. J. Nucl. Med. 46, 455-463 (2005).
36. Roques, B. P. et al. The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice. Nature 288, 286-288 (1980). (Pubitemid 11165881)